Merck & Co., Inc. (MRK)

NYSE: MRK · Real-Time Price · USD
99.86
+2.42 (2.48%)
Nov 21, 2024, 4:00 PM EST - Market closed
2.48%
Market Cap 252.61B
Revenue (ttm) 63.17B
Net Income (ttm) 12.15B
Shares Out 2.53B
EPS (ttm) 4.78
PE Ratio 20.89
Forward PE 10.96
Dividend $3.08 (3.08%)
Ex-Dividend Date Sep 16, 2024
Volume 12,019,927
Open 97.72
Previous Close 97.44
Day's Range 96.95 - 100.48
52-Week Range 94.48 - 134.63
Beta 0.41
Analysts Buy
Price Target 132.08 (+32.27%)
Earnings Date Oct 31, 2024

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]

Sector Healthcare
Founded 2000
Employees 72,000
Stock Exchange NYSE
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $132.08, which is an increase of 32.27% from the latest price.

Price Target
$132.08
(32.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference

Merck & Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET Corporate Participants Joe Romanelli - President, Human Health International Marjorie Green - SVP and ...

15 hours ago - Seeking Alpha

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across mu...

20 hours ago - Business Wire

Merck Announces First-Quarter 2025 Dividend

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Dividend.

2 days ago - Business Wire

Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Mark...

2 days ago - Seeking Alpha

Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.

The company has been preparing for the 2028 expiration of its patents protecting Keytruda.

2 days ago - Barrons

Injectable version of cancer drug Keytruda works as well as current IV form: Merck

CNBC's Angelica Peebles reports on news from Merck.

2 days ago - CNBC Television

Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation

The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.

2 days ago - Market Watch

Merck says Keytruda injection on par with approved IV version in trial

Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more...

2 days ago - Reuters

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 tri...

2 days ago - Business Wire

Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases i...

4 days ago - Seeking Alpha

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...

Other symbols: GSKJNJLLYMRNAPFE
6 days ago - Forbes

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

Other symbols: AZNBNTXGSKINOSNYVALN
6 days ago - Benzinga

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Produ...

6 days ago - Business Wire

100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys

Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sust...

Other symbols: AGRAWKBACBALLBBYBENCEG
7 days ago - Seeking Alpha

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 ...

7 days ago - Seeking Alpha

Merck to Participate in the Jefferies London Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.

7 days ago - Business Wire

Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,.

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By...

7 days ago - GlobeNewsWire

Merck signs $3.3 bln deal for experimental cancer drug

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.

7 days ago - Reuters

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today...

7 days ago - Business Wire

Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinic...

8 days ago - Seeking Alpha

KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs.

9 days ago - Business Wire

Merck: An Undervalued Dividend Machine

Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the onc...

14 days ago - Seeking Alpha

Is MRK Stock Undervalued At $100?

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared t...

15 days ago - Forbes

Merck to Participate in the UBS Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the UBS Global Healthcare Conference.

15 days ago - Business Wire

Top 2 pharma stocks to buy amid surge in deadly fungi

Recent data cited by Bloomberg reveals that deadly fungi, including Candida auris, have been spreading globally since the COVID-19 pandemic. Climate change has enabled many of these illness-causing ag...

Other symbols: GILD
17 days ago - Invezz